PHAT today
$6.23-$0.05 (-0.80%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourAscending Triangle
15 minBearish
5 minSymmetric Triangle
Daily trend turns up above $7.48
Key levels
Resistance$7.48
Resistance$6.86
Support$6.13
Support$5.04
Latest news & SEC filings
NewsPhathom Pharmaceuticals receives top biopharma honor at 2026 BioTech Breakthrough Awards
ProductPhathom Pharmaceuticals offers no-cost patient payment plan for VOQUEZNA with BlinkRx
ProductPhathom Pharmaceuticals offers $0 copay for VOQUEZNA via BlinkRx
All PHAT news →About Phathom Pharmaceuticals
Phathom Pharmaceuticals develops and sells medicines for digestive tract conditions. Its VOQUEZNA line is built on vonoprazan, an oral drug that suppresses stomach acid, and is cleared in America for GERD, heartburn, and H. pylori infection. The company sells these drugs domestically to gastroenterologists, other doctors, and via wholesalers and pharmacies. It acquired rights to vonoprazan for North America and certain other regions from Takeda.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Phathom Pharmaceuticals, Inc. (PHAT)
What Is the Price Target for PHAT?
SEPT Low Target
$15.30
SEPT Mid Target
$18.00
SEPT High Target
$20.70
Analyst Consensus
$18.00
Is PHAT a Buy or Sell Right Now?
Thesis
- •Revenue growing 216.9% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PHAT.
Start Free Trial →Is PHAT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$18.00
60
Moat Score
NARROW
4/9
Piotroski Score
-8.6
Altman Z-Score
What Is Smart Money Doing with PHAT?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Narula Sanjeev | officer | Sale | 13,485 | $91K | Oct 6, 2026 |
| Parikh Asit | director | Sale | 28,000 | - | May 22, 2026 |
| Parikh Asit | director | Buy | 17,500 | $87K | May 20, 2026 |
| Parikh Asit | director | Buy | 24,122 | - | May 19, 2026 |
| Topper James N | director 10% owner | Buy | 24,122 | - | May 19, 2026 |
| Stenhouse Mark | director | Buy | 24,122 | - | May 19, 2026 |
| FIELDS HEIDI | director | Buy | 24,122 | - | May 19, 2026 |
| COLA MICHAEL F | director | Buy | 24,122 | - | May 19, 2026 |
| KARBE FRANK | director | Buy | 24,122 | - | May 19, 2026 |
| Schroeder Theodore R | director | Buy | 24,122 | - | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PHAT Growth Story
Revenue YoY
216.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
42.72%
FCF Growth YoY
37.4%
Revenue Trend
STRONG
Dark Pool Trades for PHAT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PHAT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:30:36 | $6.26 | 1,700 | $$11K | BUY |
| 19:21:17 | $6.24 | 1,600 | $$10K | BUY |
| 18:59:00 | $6.23 | 1,575 | $$10K | SELL |
| 18:50:34 | $6.25 | 1,100 | $$7K | BUY |
| 18:45:48 | $6.26 | 1,143 | $$7K | BUY |
5 dark pool trades shown · $$44K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Phathom Pharmaceuticals, Inc. (PHAT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PHAT — frequently asked questions
What is PHAT stock price today?
Phathom Pharmaceuticals, Inc. (PHAT) is at $6.23, down 0.80% (-$0.05) at the Nov 12, 2026 close.
Why is PHAT stock moving today?
Latest PHAT news — Nov 5, 2026: Phathom Pharmaceuticals receives top biopharma honor at 2026 BioTech Breakthrough Awards · Nov 3, 2026: Phathom Pharmaceuticals offers no-cost patient payment plan for VOQUEZNA with BlinkRx
What is the PHAT price target?
The average analyst price target for PHAT is $18.00, ranging from $10 to $26, based on 4 analysts. Latest: Leerink Partners initiates on Sep 9, 2026.
What do analysts rate PHAT?
Analyst ratings for PHAT: 1 Buy, 5 Hold, 0 Sell — consensus Hold.
Did PHAT beat earnings?
PHAT last reported on Jul 30, 2026: EPS -$0.21 vs -$0.18 expected — a miss of 19.6%.
Does PHAT pay a dividend?
PHAT does not currently pay a dividend.
How much debt does PHAT have?
Phathom Pharmaceuticals, Inc. reported $165M of debt and $182M of cash (Jun 30, 2026).
What are PHAT support and resistance levels?
Support: $6.13, $5.04, $4.47. Resistance: $6.86, $7.48, $8.21.
What are insiders doing with PHAT?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on PHAT?
Nov 5, 2026: Phathom Pharmaceuticals receives top biopharma honor at 2026 BioTech Breakthrough Awards · Nov 3, 2026: Phathom Pharmaceuticals offers no-cost patient payment plan for VOQUEZNA with BlinkRx · Nov 3, 2026: Phathom Pharmaceuticals offers $0 copay for VOQUEZNA via BlinkRx